In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Privia Health Group shows significant undervaluation with a current price of $25.01 against a fair value near $49.62, implying nearly 98% upside. High leverage and low profitability heighten financial risk, while Monte Carlo scenarios reveal a wide value range and 11.1% downside risk below current price. Valuation confidence remains high despite efficiency and growth concerns.